Series

Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock

Retrieved on: 
Friday, July 29, 2022

ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc.. (NYSE American: SYN) (Synthetic Biologics or the Company), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the private placement of 275,000 shares of Series C convertible preferred stock and 100,000 shares of Series D convertible preferred stock.

Key Points: 
  • ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc.. (NYSE American: SYN) (Synthetic Biologics or the Company), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the private placement of 275,000 shares of Series C convertible preferred stock and 100,000 shares of Series D convertible preferred stock.
  • Each share of Series C and Series D preferred stock has a purchase price of $8.00.
  • Each share of Series C and Series D preferred stock is convertible into shares of the Companys common stock at an initial conversion price of $1.22 per share.
  • The Series D preferred stock permits the holder to cast 20,000 votes per share of Series D preferred stock on such proposals, provided, that such votes must be cast in the same proportions as the shares of common stock and Series C preferred stock are voted on such proposals.

American Equity Declares 3rd Quarter 2022 Preferred Stock Dividends

Retrieved on: 
Friday, July 29, 2022

The dividend will be payable on September 1, 2022 to Series A Preferred Stock shareholders of record as of August 15, 2022.

Key Points: 
  • The dividend will be payable on September 1, 2022 to Series A Preferred Stock shareholders of record as of August 15, 2022.
  • Depositary receipts for the Series A Preferred Stock are listed on the New York Stock Exchange (NYSE) under the ticker symbol AELPRA.
  • Additionally, American Equity Investment Life Holding Company today announced that in accordance with the terms of its 6.625% Fixed-Rate Reset Non-Cumulative Preferred Stock, Series B (the Series B Preferred Stock), which is represented by depositary shares, each representing a 1/1,000th interest in a share of Series B Preferred Stock (the Series B Depositary Shares), the Board of Directors has declared a cash dividend of $414.0625000 per share of Series B Preferred Stock (equivalent to $0.414062500 per Depositary Share).
  • The dividend will be payable on September 1, 2022 to Series B Preferred Stock shareholders of record as of August 15, 2022.

Zions Bancorporation’s Board Approves Share Repurchase and Declares Dividends on Common and Preferred Stock

Retrieved on: 
Friday, July 29, 2022

(NASDAQ: ZION) announced today that its board of directors (board) authorized a share repurchase for the third quarter of 2022 of up to $50 million.

Key Points: 
  • (NASDAQ: ZION) announced today that its board of directors (board) authorized a share repurchase for the third quarter of 2022 of up to $50 million.
  • The board also declared a regular quarterly dividend of $0.41 per common share, payable August 25, 2022, to shareholders of record at the close of business on August 18, 2022.
  • Additionally, the board declared regular quarterly cash dividends on the company's various perpetual preferred shares, as detailed below.
  • Zions has obtained the requisite regulatory approval to allow Zions to timely execute on this authorization.

Trevena, Inc. Announces Registered Direct Offering of Preferred Stock

Retrieved on: 
Friday, July 29, 2022

Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share.

Key Points: 
  • Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share.
  • The shares of preferred stock issued in the offering are convertible into an aggregate of 8,000,000 shares of common stock.
  • The shares of preferred stock are convertible at the option of the holder at any time following the date of issuance.
  • Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is $2 million.

RPT Realty Declares Third Quarter 2022 Common and Preferred Share Dividends

Retrieved on: 
Thursday, July 28, 2022

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- RPT Realty (NYSE:RPT) (RPT or the Company) announced today that its Board of Trustees declared a third quarter 2022 regular cash dividend of $0.13 per common share.

Key Points: 
  • NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- RPT Realty (NYSE:RPT) (RPT or the Company) announced today that its Board of Trustees declared a third quarter 2022 regular cash dividend of $0.13 per common share.
  • The Board of Trustees also approved a third quarter 2022 Series D convertible preferred share dividend of $0.90625 per share.
  • The dividends, for the period July 1, 2022 through September 30, 2022 are payable on October 3, 2022 for shareholders of record on September 20, 2022.
  • The common shares of the Company, par value $0.01 per share (the common shares) are listed and traded on the NYSE under the ticker symbol RPT.

Retool Raises $45M Series C2 to Change How Software Is Built

Retrieved on: 
Thursday, July 28, 2022

The San Francisco-based company raised $20 million in Series C funding in December 2021, opting for a smaller round.

Key Points: 
  • The San Francisco-based company raised $20 million in Series C funding in December 2021, opting for a smaller round.
  • Retool will primarily use its funds to invest more aggressively in headcount, new products and platform improvements, and international expansion.
  • Broadening access to the Retool platform is a key step in our mission to change the way the world develops software, said Hsu.
  • Thousands of teams at companies like Amazon, DoorDash, Snowflake, and Brex collaborate around custom-built Retool apps to solve internal workflows.

SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments

Retrieved on: 
Thursday, July 28, 2022

SEngine's CLIA certified PARISTest generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer.

Key Points: 
  • SEngine's CLIA certified PARISTest generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer.
  • Investor participation was spurred by the continued momentum of SEngines platform in both drug discovery and clinical diagnostics.
  • SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures utilizing patient specific tumor cells.
  • SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies by deploying its precision oncology platform.

Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

Retrieved on: 
Thursday, July 28, 2022

Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.

Key Points: 
  • Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.
  • Many diseases, including cancer and monogenic diseases, are often caused by specific proteins that are abnormally degraded and lost from the cell.
  • In cancer, protective tumor suppressors are aberrantly destroyed, allowing cancer cells to circumvent cell death, thus promoting unobstructed cell proliferation.
  • Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs).

Led by Legend Capital, The Leading Intelligent Special Robot Company AKA Robotics Completes Series A Financing

Retrieved on: 
Thursday, July 28, 2022

HONG KONG, July 28, 2022 - (ACN Newswire) - Shenzhen AKA Robotics Technology Co., LTD. (hereinafter referred to as "AKA Robotics"), a leading intelligent special robot company, recently completed its Series A financing round, which was led by Legend Capital.

Key Points: 
  • HONG KONG, July 28, 2022 - (ACN Newswire) - Shenzhen AKA Robotics Technology Co., LTD. (hereinafter referred to as "AKA Robotics"), a leading intelligent special robot company, recently completed its Series A financing round, which was led by Legend Capital.
  • The founding team of AKA Robotics was formed by experts in the field of robotics, coming from Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences.
  • AKA Robotics has taken the lead in forming large-scale applications in ships and is a leading enterprise in special robots.
  • At the same time, Legend Capital will continue to support AKA Robotics in growing into a global and platform-based special robot company by providing more proactive value-added services."

Olympus Innovation Ventures Backs Endoscopy Video and AI Company, Virgo Surgical Video Solutions

Retrieved on: 
Wednesday, July 27, 2022

CENTER VALLEY, Pa., July 27, 2022 /PRNewswire/ -- Olympus today announced that the company's venture capital fund, Olympus Innovation Ventures, completed its first investment, participating in the Series A financing of Virgo Surgical Video Solutions ("Virgo") of Carlsbad, California.  The Olympus corporate venture capital fund makes investments in emerging digital, device, and diagnostic companies in minimally invasive detection and treatment of disease in gastroenterology, urology, respiratory care and other clinical areas.

Key Points: 
  • CENTER VALLEY, Pa., July 27, 2022 /PRNewswire/ -- Olympus today announced that the company's venture capital fund, Olympus Innovation Ventures, completed its first investment, participating in the Series A financing of Virgo Surgical Video Solutions ("Virgo") of Carlsbad, California.
  • Virgo also leverages endoscopy video data and AI to identify patient candidates for inflammatory bowel disease clinical trials.
  • More information about Olympus Innovation Ventures, which is managed together with Touchdown Ventures , is available at olympusamerica.com/olympus-venture-capital .
  • Virgo Surgical Video Solutions provides the leading cloud video capture, management, and artificial intelligence analysis platform for endoscopic medicine.